Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 7 of 14

8. Palvella Therapeutics Inc (NASDAQ:PVLA)

Number of Hedge Fund Holders In Q4 2024: 9

Palvella Therapeutics Inc (NASDAQ:PVLA) is a clinical-stage biopharmaceutical company that makes therapies for rare genetic skin diseases with no FDA-approved therapies.

The stock is up significantly so far in 2025 after Palvella’s announcement on February 10, 2025, that it would expand its Phase 3 SELVA clinical trial of QTORIN™ rapamycin for microcystic lymphatic malformations to include younger pediatric patients aged 3 to 5 years old.

Before that, Palvella announced the publication of results from its Phase 2 clinical trial of QTORIN™ rapamycin for microcystic lymphatic malformations in the Journal of Vascular Anomalies, reporting that 100% of participants were either “Much Improved” or “Very Much Improved” as rated by the Clinician Global Impression of Change.

It also announced that the first patients had been dosed in its Phase 2 TOIVA clinical trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations.

The consensus price target of $40.33 implies 113.97% upside.

PVLA is up 56.17% year-to-date.

Page 7 of 14